👉Another great opportunity to learn more about our work is the poster session B happening on October 24th where Irmela presents how "A CRISPR/Cas9 pipeline in patient-derived xenograft models in vivo identifies attractive therapeutic targets" (LB-B020).

#PDX #CRISPR

We are happy to connect!

Annika Fröhlich will dive into exciting preclinical in vivo trials using serially transplantable, genetically engineered PDX models showing how a novel Decitabine analogue is pushing boundaries in AML treatment—delivering potent anti-leukemia effects with a significantly improved safety profile 🚀

This platform provides excellent new opportunities for translational research in AML 🚀.

Don’t hesitate to contact us if you are interested in *PDX AML models.

Many thanks to all collaborators and co-authors who made this work possible!

#Leukemia #AML #PDX #TranslationalResearch #Preprint

In one year-long in vivo trials mimicking clinical chemotherapy, we observed a surprising pattern:

📉 leukemia growth gradually declined after each treatment block

These *PDX models allow:
🔄 serial transplantation
🧬 genetic engineering
🐁 functional and molecular studies, both in vivo and ex vivo
🧪 faithful representation of primary AML biology – beyond what cell lines can deliver.

We present robust AML PDX models (*PDX) covering subgroups where no cell lines exist – opening new doors for ex vivo and in vivo studies.

These *PDX models allow:

🔄 serial transplantation
🧬 genetic engineering
🐁 functional and molecular studies, both in vivo and ex vivo
🧪 faithful representation of primary AML biology – beyond what cell lines can deliver.

We present robust AML PDX models (*PDX) covering subgroups where no cell lines exist – opening new doors for ex vivo and in vivo studies.

P27 @sercoz.bsky.social
In vivo CRISPR-Cas9 screening in PDX models reveals CCND3 as a new therapeutic vulnerability

P39 @binjev.bsky.social
Serially transplantable PDX models for AML subtypes for which no cell lines exist

If you’re attending, don’t miss our posters! We’ll be sharing our latest research using genetically engineered Acute Leukemia PDX models—and we’d love to connect with you.

P18 @kkuhbandner.bsky.social
A novel Decitabine analogue with enhanced anti-leukemia activity and reduced toxicity in vivo

Many thanks to Jan-Henning Klusmann, Olaf Heidenreich, @rolfmarschalek.bsky.social and Martin Stanulla for the organization!

See you there 😀!

Visit our poster “A CRISPR/Cas9 pipeline to uncover potential therapeutic targets in PDX models of acute lymphoblastic leukemia" and learn more about our work.

Looking forward to connecting with fellow researchers in the ALL field. See you there!

Looking forward to connecting with fellow pediatricians and presenting our latest findings on patient-derived xenograft models for AML.

🗣️ Don't miss Irmela‘s talk about "Serially transplantable PDX models for AML subtypes for which no cell lines exist“